Emergent Biosolutions, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $12.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ram Selvaraju has given his Buy rating due to a combination of factors tied to Emergent BioSolutions’ recent contract momentum and strategic positioning. He highlights newly secured government awards totaling about $60M, including a sizeable U.S. ASPR order for VIGIV and additional international demand for ACAM2000, which reinforce the strength and repeatability of the firm’s contract-driven MCM business model.
Selvaraju also argues that rising geopolitical instability and evolving biothreats could further bolster long-term need for Emergent’s biodefense and nerve-agent countermeasure products. Using a DCF framework with what he views as conservative assumptions, he arrives at an enterprise value that supports a $12 per-share target, while acknowledging competitive, regulatory, and execution risks that investors should monitor.